European Launch

Advanced Medical Solutions Grp PLC
06 July 2005


For immediate release                                              6th July 2005


                      Advanced Medical Solutions Group plc
                            ('AMS' or 'the Company')

        Launches superglue product for closing keyhole surgery wounds

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
woundcare technology company, today announces that it has introduced a novel
product for use in closing wounds after keyhole (laparoscopic) surgery
throughout Europe.

The product, LiquiBand Laparoscopic(TM), will form part of the family of medical
adhesives based on superglue technology sold by AMS through its MedLogic wound
closure division.  These products which are sold direct to hospitals in the UK
and through marketing and distribution partners throughout the rest of Europe,
such as Baxter Healthcare in France and Spain and Resorba Clinicare in Germany,
are used to close wounds in the Accident and Emergency (A&E) department and in
operating theatres, instead of the conventional use of sutures and staples.

AMS is market leader in the use of skin closure glues in A&E in the UK under the
LiquiBandTM brand, and has introduced a product designed for use in closing
surgical incisions in the operating theatre (LiquiBand SurgicalTM).

It is estimated that there are currently around 1 million procedures performed
by laparoscopic surgery in Europe.  These include many gynaecological procedures
and routine general surgery operations such as gall bladder removal and hernia
repair where the use of minimally invasive surgery offers real benefit to the
patient, surgeon and healthcare systems.  The subsequent closure of these small
incisions with glue offers major benefits over the use of conventional methods
such as sutures and staples.

LiquiBand Laparoscopic(TM) is a two-part adhesive system and combines fast,
strong, secure closure of the skin whilst providing occlusive wound protection
resulting in reduced trauma, reduced risk of infection, excellent cosmetic
outcomes and no sutures or staples to remove.

The new product was introduced at a major meeting in the UK attended by
marketing and distribution partners and surgeons from around Europe. The use of
the product in a range of surgical procedures was demonstrated through live
surgery by UK surgeon champions.  The product has subsequently been launched and
is now available for sale in most countries throughout Europe.

Commenting on today's announcement, Dr. Don Evans, Chief Executive of AMS, said:
'LiquiBand Laparoscopic(TM) is an exciting new product that offers real clinical
and patient benefits for the closure of these small incisions resulting from
laparoscopic procedures.  As the number of these procedures continues to
increase, the potential for this product is significant as it should become the
standard of care.  We are in an excellent position to lead this trend throughout
Europe on the back of our strong direct presence in the UK and our marketing and
distribution partners in the other major markets.'


                                    - ENDS -


For further information, please contact:

Advanced Medical Solutions Group plc                   Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com

Buchanan Communications                                Tel: [phone]
Mark Court, Mary-Jane Johnson


Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Smith + Nephew and Cardinal Health.


                      This information is provided by RNS
            The company news service from the London Stock Exchange